Objective—To compare the Kiupel (2 categories) and Patnaik (3 categories) histologic grading systems for predicting the presence of metastasis at the time of initial examination in dogs with cutaneous mast cell tumors (MCTs). Design—Retrospective case series. Animals—386 client-owned dogs with cutaneous MCTs. Procedures—Medical records of dogs with newly diagnosed, histologically confirmed cutaneous MCTs that had undergone complete clinical staging were reviewed for clinical and histopathologic data. Results—All Patnaik grade 1 MCTs (n = 52) were classified as Kiupel low-grade MCTs, and all Patnaik grade 3 MCTs (43) were classified as Kiupel high-grade MCTs. Of the 291 Patnaik grade 2 MCTs, 243 (83.5%) were classified as Kiupel low-grade tumors, and 48 (16.5%) were classified as Kiupel high-grade MCTs. Dogs with Patnaik grade 3 MCTs were significantly more likely to have metastases at the time of initial examination than were dogs with grade 1 or 2 MCTs (OR, 5.46), and dogs with Kiupel high-grade MCTs were significantly more likely to have metastases than were dogs with Kiupel low-grade MCTs (OR, 2.54). However, 3 of 52 (5.8%) dogs with Patnaik grade 1 tumors, 48 of 291 (16.5%) dogs with Patnaik grade 2 tumors, and 44 of 295 (14.9%) dogs with Kiupel low-grade tumors had metastatic disease. Conclusions and Clinical Relevance—Findings indicated that in dogs with cutaneous MCTs, prognostication should not rely on histologic grade alone, regardless of grading system used, but should take into account results of clinical staging.

Objective—To describe clinical characteristics, treatment, and outcome of dogs with inflammatory carcinoma (IC) and identify patient-, tumor-, and treatment-related factors associated with overall survival time. Design—Retrospective case series. Animals—43 client-owned dogs. Procedures—Records of dogs with a clinical diagnosis of IC that had histologic evidence of dermal lymphatic invasion were reviewed. Data on clinical staging, treatment, toxicoses, response, and survival time were retrieved. Results—26 (60%) dogs had primary IC and 17 (40%) had secondary IC. Thirty-five (81%) dogs had distant metastases and 2 (5%) had local metastases at the time of initial examination. Six of 29 (21%) dogs had a coagulopathy. Sixteen (37%) dogs did not receive specific treatment for IC, 24 (56%) received medical treatment only, 2 (5%) underwent surgical excision and received medical treatment, and 1 (2%) underwent surgical excision only. Forty-one (95%) dogs had progressive disease, and 2 (5%) had stable disease. Mean survival time for all dogs was 60 days (range, 1 to 300 days). Dogs with a coagulopathy survived a significantly shorter time than did dogs without a coagulopathy (odds ratio, 0.28), and dogs that received medical treatment survived significantly longer than dogs that did not (odds ratio, 2.54). Conclusions and Clinical Relevance—Results suggested that mammary IC is a biologically aggressive condition in dogs associated with a guarded prognosis. In addition, results suggested that medical treatment may improve outcome, thereby supporting its use in dogs with IC.

The prevalence of gastrointestinal parasites was investigated in mammals housed in two of the main Italian zoological gardens: the Zoo Safari of Fasano (province of Bindisi, Apulia, Italy) and the Giardino Zoologico of Pistoia (Tuscany, Italy). In November 2007, fecal samples were collected at the Zoo Safari of Fasano (n = 96) and at the Giardino Zoologico of Pistoia (n = 60), from primates, carnivores, perissodactyls, artiodactyls and proboscideans. In most of the cases, the same animal species or genera were considered in both the zoos. One or more intestinal parasites were detected in 61.5% of the examined samples. However, very different percentages of protozoa- and helminth-positive samples were obtained in the animals from the two zoos, with an overall gastrointestinal parasitic infection of 77.1% in the Zoo Safari of Fasano and 36.7% in the Giardino Zoologico of Pistoia. Overall, 10% (Cryptosporidium sp.) and 43.3% (Toxocara cati, Strongyloides stercoralis, Toxascaris leonina, and hook...

Objective—To evaluate whether serial determinations of serum lactate dehydrogenase (LDH) activity in dogs with lymphoma could be used to predict outcome and assist in early recognition of disease progression. Design—Prospective cohort study. Animals—50 dogs with lymphoma. Procedures—LDH activity was determined in dogs with newly diagnosed lymphoma or that had not received treatment. The LDH activity was measured at time of initial diagnosis, at completion of chemotherapy, and at 1, 3, and 6 months after chemotherapy. Treatment response and recurrence were recorded. At the end of chemotherapy and at each time point thereafter, the proportion of dogs in complete remission with elevated LDH activity was compared between dogs that did or did not have recurrence within the successive 45 or 90 days. Use of the LDH activity at admission to predict disease-free and survival intervals was evaluated. Results—The proportion of dogs in complete remission with increased LDH activity at completion of chemotherapy and at 1 month after chemotherapy with recurrence during the successive 45 days was significantly higher (3/9 and 7/9 dogs, respectively) than the proportion of dogs without recurrence (0/32 and 1/26 dogs, respectively). At 3 or 6 months, only 1 dog without recurrence within 45 days had increased LDH activity. Increased LDH activity at time of diagnosis was not associated with disease-free and survival intervals. Conclusions and Clinical Relevance—Determination of LDH activity may help with identifying episodes of recurrence in dogs with lymphoma. Anticipation of recurrence is an appropriate reason to begin rescue treatment.